Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
David Mehalick Insider Profile
11 Followers
David Mehalick, CEO and President, Director, Ten Percent Owner at Coeptis Therapeutics, holds 2.78M shares in Coeptis Therapeutics Holdings (Ticker: COEP), holds 1.80M shares in Coeptis Therapeutics (Ticker: ~COEP). Most recently, David Mehalick Bought ― shares of Coeptis Therapeutics Holdings on Jan 09, 2024 for an estimated value of 16.75K.
David Mehalick Coeptis Therapeutics (~COEP)CEO and President, Director, Ten Percent Owner
Coeptis Therapeutics (~COEP)
CEO and President, Director, Ten Percent Owner
Not Ranked
David Mehalick has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
CEO & President, Director, Ten Percent Owner
Roles that David Mehalick holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jan 09, 2024 - Today
Return:-45.80%
The most profitable trade made by David Mehalick
David Mehalick's Trading History
Coeptis Therapeutics
Nov 18, 2021
―
Uninformative Sell
―
$6.03M
Coeptis Therapeutics Holdings
Jan 09, 2024
CEO & President, Director, Ten Percent Owner
Informative Buy
16.75K
$973.92K
List of latest transactions for each holding click on a transaction to see David Mehalick's performance on stock
You May Also Like
David Mehalick insider profile FAQ
What is the percentage of profitable transactions made by David Mehalick?
The percentage of profitable transactions made by David Mehalick is ―.
What is the average return per transaction made by David Mehalick?
The average return per transaction made by David Mehalick is ―.
What stocks does David Mehalick hold?
David Mehalick holds: ~COEP, COEP stocks.
What was David Mehalick’s latest transaction?
David Mehalick latest transaction was an Informative Buy of $16.75K.
What was David Mehalick's most profitable transaction?
David Mehalick’s most profitable transaction was an Informative Buy of COEP stock on January 9, 2024. The return on the trade was -45.80%.
What is David Mehalick's role in Coeptis Therapeutics?
David Mehalick's role in Coeptis Therapeutics is CEO and President, Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.